View Item 

Show simple item record

Reply to “Is there a role for combined anti–PD-1/CTLA-4 checkpoint blockade in the management of advanced biliary tract cancers?”
dc.contributor.authorSahai, Vaibhav
dc.contributor.authorZalupski, Mark M.
dc.date.accessioned2023-04-04T17:38:58Z
dc.date.available2024-05-04 13:38:57en
dc.date.available2023-04-04T17:38:58Z
dc.date.issued2023-04-01
dc.identifier.citationSahai, Vaibhav; Zalupski, Mark M. (2023). "Reply to “Is there a role for combined anti–PD-1/CTLA-4 checkpoint blockade in the management of advanced biliary tract cancers?”." Cancer 129(7): 1131-1132.
dc.identifier.issn0008-543X
dc.identifier.issn1097-0142
dc.identifier.urihttps://hdl.handle.net/2027.42/176022
dc.publisherWiley Periodicals, Inc.
dc.titleReply to “Is there a role for combined anti–PD-1/CTLA-4 checkpoint blockade in the management of advanced biliary tract cancers?”
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelPublic Health
dc.subject.hlbsecondlevelOncology and Hematology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/176022/1/cncr34659_am.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/176022/2/cncr34659.pdf
dc.identifier.doi10.1002/cncr.34659
dc.identifier.sourceCancer
dc.identifier.citedreferenceDoki Y, Ueno M, Hsu CH, et al. Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head-and-neck cancer. Cancer Med. 2022; 11 ( 13 ): 2550 - 2560. doi: 10.1002/cam4.4593
dc.identifier.citedreferenceEdenfield WJ, Chung K, O’Rourke M, et al. A phase II study of durvalumab in combination with tremelimumab in patients with rare cancers. Oncologist. 2021; 26 ( 9 ): e1499 - e1507. doi: 10.1002/onco.13798
dc.identifier.citedreferenceIoka T, Ueno M, Oh DY, et al. Evaluation of safety and tolerability of durvalumab (D) with or without tremelimumab (T) in patients (pts) with biliary tract cancer (BTC). J Clin Oncol. 2019; 37 ( 4)(suppl l ): 387. doi: 10.1200/jco.2019.37.4_suppl.387
dc.identifier.citedreferenceKlein O, Kee D, Nagrial A, et al. Evaluation of combination nivolumab and ipilimumab immunotherapy in patients with advanced biliary tract cancers: subgroup analysis of a phase 2 nonrandomized clinical trial. JAMA Oncol. 2020; 6 ( 9 ): 1405 - 1409. doi: 10.1001/jamaoncol.2020.2814
dc.identifier.citedreferenceSahai V, Griffith KA, Beg MS, et al. A randomized phase 2 trial of nivolumab, gemcitabine, and cisplatin or nivolumab and ipilimumab in previously untreated advanced biliary cancer: BilT-01. Cancer. 2022; 128 ( 19 ): 3523 - 3530. doi: 10.1002/cncr.34394
dc.identifier.citedreferenceDelaye M, Assenat E, Dahan L, et al. Durvalumab (D) plus tremelimumab (T) immunotherapy in patients (Pts) with advanced biliary tract carcinoma (BTC) after failure of platinum-based chemotherapy (CTx): interim results of the IMMUNOBIL GERCOR D18-1 PRODIGE-57 study. J Clin Oncol. 2022; 40 ( 16 suppl l ): 4108. doi: 10.1200/jco.2022.40.16_suppl.4108
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
cncr34659_am.pdf
Size:
482.0KB
Format:
PDF
View/Open
Name:
cncr34659.pdf
Size:
163.6KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.